Potential opportunities for treatment of metabolic syndrome withalpha-lipoic acid (Berlithion®300)
| Autor: | Romantsova T I, Kuznetsov I S |
|---|---|
| Rok vydání: | 2009 |
| Předmět: |
medicine.medical_specialty
Physiology Endocrinology Diabetes and Metabolism Peroxisome proliferator-activated receptor Adipose tissue QD415-436 Oxidative phosphorylation Biology Biochemistry metabolic syndrome chemistry.chemical_compound Endocrinology Adipocyte Internal medicine Brown adipose tissue Internal Medicine medicine QP1-981 Uncoupling protein peroxisome proliferator activated receptor chemistry.chemical_classification Nutrition and Dietetics Public Health Environmental and Occupational Health AMPK adenosine monophosphate - activated protein kinase Lipoic acid medicine.anatomical_structure uncoupling protein chemistry |
| Zdroj: | Ожирение и метаболизм, Vol 6, Iss 3, Pp 10-14 (2009) |
| ISSN: | 2306-5524 2071-8713 |
| DOI: | 10.14341/2071-8713-5240 |
| Popis: | There are a lot of experi mental data confirmed the influence of alpha-lipoi с acid on activity of AMPK enzyme, receptors PPARα/γ and uncoupling proteins that prev ent oxidative phosphorylation (UCPl). AMPK is the enzyme responsible for food intake and energy expenditure in hypothalamus as w ell as in peripheral adipose tissue. PPARγ is the key modulator of lipid ho meostasis and adipocyte differentiation. UCPl is located in the brown adipose tissue and provides termogenesis. Via regulation of mentioned biological targets alpha-lipoic acid (Berlithion®300) lowers insulinresistance, favors weight losing process and improvement of blood lipid profile. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|